Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-02-24
2011-11-29
Loewe, Sun Jae (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S331000
Reexamination Certificate
active
08067379
ABSTRACT:
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
REFERENCES:
patent: 5712145 (1998-01-01), Houghton et al.
patent: 6608027 (2003-08-01), Tsantrizos et al.
patent: 6911428 (2005-06-01), Zhu et al.
patent: 7012066 (2006-03-01), Saksena et al.
patent: 7244721 (2007-07-01), Saksena et al.
patent: 7816326 (2010-10-01), Velazquez et al.
patent: 2003/0216325 (2003-11-01), Saksena et al.
patent: 2007/0197448 (2007-08-01), Velazquez et al.
patent: 98-14181 (1998-04-01), None
patent: 98-17679 (1998-04-01), None
patent: 98-22496 (1998-05-01), None
patent: 99-07734 (1999-02-01), None
patent: 00-09543 (2000-02-01), None
patent: 00-09558 (2000-02-01), None
patent: WO 00/09543 (2000-02-01), None
patent: 01-74768 (2001-10-01), None
patent: 01-77113 (2001-10-01), None
patent: 01-81325 (2001-11-01), None
patent: 02-08187 (2002-01-01), None
patent: 02-08244 (2002-01-01), None
patent: 02-08251 (2002-01-01), None
patent: 02-08256 (2002-01-01), None
patent: WO 02/08244 (2002-01-01), None
patent: WO 02/18369 (2002-03-01), None
patent: 02-48172 (2002-06-01), None
patent: WO 03/062265 (2003-07-01), None
patent: 2005-087731 (2005-09-01), None
patent: 2006-130628 (2006-12-01), None
Newman et al., DDT vol. 8, Oct. 2003, p. 898-90.
Chawla et al., CRIPS vol. 5, No. 1, Jan.-Mar. 2004, p. 9-12.
Saksena et al., caplus an 2002:90062.
International Search Report for PCT/US2005/005795—6 Pages.
Berenguer et al., “Hepatitis B and C Viruses: Molecular Identification and Targeted Antiviral Therapies”, Proceedings of the Association of American Physicians, 110(2):98-112 (1998).
Dimasi et al., “Characterization of Engineered Hepatitis C Virus NS3 Protease Inhibitors Affinity Selected from Human Pancreatic Secretory Trypsin Inhibitor and Minibody Repertoires”, Journal of Virology, 71(10):7461-7469 (1997).
Elzouki et al., “Serine Protease Inhibitors in Patients with Chronic Viral Hepatitis”, Journal of Hepatology, 27:42-48 (1997).
Failla et al., “Redesigning the Substrate Specificity of the Hepatitis C Virus NS3 Protease”, Folding & Design, 1(1):35-42 (1996).
Han et al., “alpha-Ketoamides, alpha-Ketoesters and alpha-Diketones as HCV NS3 Protease Inhibitors”, Bioorganic & Medicinal Chemistry Letters, 10:711-713 (2000).
Hoofnagle et al., “The Treatment of Chronic Viral Hepatitis”, The New England Journal of Medicine, 336(5):347-356 (1997).
Ingallinella et al., “Potent Peptide Inhibitors of Human Hepatitis C Virus NS3 Protease are Obtained by Optimizing the Cleavage Products”, Biochemistry, 37:8906-8914 (1998).
Kolykhalov et al., “Specifically of the Hepatitis C Virus NS3 Serine Protease: Effects of Substitutions at the 3/4A, 4A/4B, 4B/5A, and 5A/5B Cleavage Sites on Polyprotein Processing”, Journal of Virology, 68(11):7525-7533 (1994).
Komoda et al., “Substrate Requirements of Hepatitis C Virus Serine Proteinase for Intermolecular Polypeptides Cleavage inEscherichia coli”, Journal of Virology, 68(11):7351-7357 (1994).
Landro et al., “Mechanistic Role of an NS4A Peptide Cofactor with the Truncated NS3 Protease of Hepatitis C Virus: Elucidation of the NS4A Stimulatory Effect via Kinetic Analysis and Inhibitor Mapping”, Biochemistry, 36:9340-9348 (1997).
Pizzi et al., “Molecular Model of the Specificity Pocket of the Hepatitis C VIrus Protease: Implications for Substrate Recognition”, Proceedings of the National Academy Sciences of the USA, 91:888-892 (1994).
Llinas-Brunet et al., “Peptide-Based Inhibitors of the Hepatitis C Virus Serine Protease”, Bioorganic & Medicinal Chemmistry Letters 8:1713-1718 (1998).
Marchetti et al., “Synthesis of Two Novel Cyclic Biphenyl Ether Analogs of an Inhibitor of HCV NS3 Protease”, Synlett S1:1000-1002 (1999).
Martin et al., “Design of Selective Eglin Inhibitors of HCV NS3 Proteinase”, Biochemistry, 37:11459-11468 (1998).
Martin, et al., “Affinity Selection of a Carmelized VH Domain Antibody Inhibitor of Hepatitis C virus NS3 Protease”, Protein Engineering, 10(5):607-614 (1997).
BioWorld Today, 9(217):1-5 (1998).
International Search Report for PCT Application No. PCT/US01/22678 dated Jun. 7, 2002.
International Search Report for PCT Application No. PCT/US2008/004549 dated Mar. 25, 2009.
Arasappan Ashok
Bennett Frank
Bogen Stephane L.
Chen Kevin X.
Girijavallabhan Viyyoor M.
Heber Sheldon O.
Lake Julie M.
Loewe Sun Jae
Schering Corporation
LandOfFree
Sulfur compounds as inhibitors of hepatitis C virus NS3... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulfur compounds as inhibitors of hepatitis C virus NS3..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfur compounds as inhibitors of hepatitis C virus NS3... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4285888